NVS 6-K: SEC filing
Novartis Capital Corporation
Filed with the SEC on · accession 0001104659-26-126289
NVS filed a 6-K (foreign company report) with the SEC on Nov 12, 2026. Novartis Capital Corporation issued $5.5 billion in aggregate principal amount of guaranteed notes across four tranches (2029, 2032, 2034, and 2037 maturities), guaranteed by Novartis AG.
Summary of the filing
Novartis Capital Corporation issued $5.5 billion in aggregate principal amount of guaranteed notes across four tranches (2029, 2032, 2034, and 2037 maturities), guaranteed by Novartis AG. The filing is for incorporation of related documents into Novartis's existing Form F-3 registration statement.
Key details
✦ Ask GOAX AI about this filing — what it means for NVS, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for NVS?
Click hereFrequently asked questions
What did NVS file with the SEC on Nov 12, 2026?
NVS filed a 6-K (SEC filing). Novartis Capital Corporation issued $5.5 billion in aggregate principal amount of guaranteed notes across four tranches (2029, 2032, 2034, and 2037 maturities), guaranteed by Novartis AG. The filing is for incorporation of related documents into Novartis's existing Form F-3 registration statement.
How do I read a 6-K?
How foreign companies listed in the US report news and events — like an 8-K for them. Look at the exhibit names: "results", "resign", "notice" tell you the topic. Many 6-Ks are routine (meeting notices); results and leadership changes matter most.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 6-K (foreign company report): How foreign companies listed in the US report news and events — like an 8-K for them.
Other NVS SEC filings
- 424B5 · Shelf registrationNov 9, 2026
- SCHEDULE 13G/A · SEC filingOct 27, 2026
- 6-K · SEC filingOct 27, 2026
- 6-K · Fda rejectionSep 8, 2026
- 6-K · Fda rejectionSep 4, 2026
- 6-K · Fda approvalSep 1, 2026
- 6-K · SEC filingJul 21, 2026
- 6-K · Fda approvalJun 11, 2026
- 144 · Insider sale plannedApr 30, 2026
- 6-K · SEC filingApr 28, 2026
Get alerts when NVS files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days